COVID-19 Law and Policy Briefings, Series One: Drug Development, the Role of the FDA, and Emergency Use
Sinha, Michael Zettler, Patricia
Sinha, Michael
Zettler, Patricia
Citations
Altmetric:
Genre
Audio recording
Date
2020-04-15
Advisor
Committee member
Department
Permanent link to this record
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.34944/dspace/7344
Abstract
This Briefing seeks to demystify drug development — offering a crash in the development process and clinical trials, the role the FDA plays in reviewing and approving drugs, and the differences between off-label and compassionate use.
Description
The COVID-19 Law and Policy Briefings, hosted in two series from March 2020 through July 2021, feature US and international public health law experts discussing the biggest legal issues arising from the COVID-19 pandemic. The briefings are produced by the George Consortium, co-sponsored by the Center for Health Policy and Law at Northeastern University School of Law, the Center for Public Health Law Research at Temple University Beasley School of Law, and the APHA Law Section. Visit Public Health Law Watch (http://bit.ly/COVIDLawBriefing) to watch episodes. All past briefings are also archived by The Week in Health Law podcast.
Citation
This Week in Health Law, COVID-19 Law and Policy Briefings, Series One: Drug Development, the Role of the FDA, and Emergency Use, (April 15, 2020), https://twihl.podbean.com/mf/play/xwn3cr/twihl_188.mp3.
Citation to related work
Has part
The Week in Health Law, Ep. 188
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu